Articles

Diabetes care has improved in the US over the last decade, but there is still plenty of room for improvement in control of cholesterol levels, blood pressure, and glycemia.

In patients with type 2 diabetes, pre-meal treatment with the alpha-glucosidase inhibitor acarbose may help protect against endothelial dysfunction and perhaps future cardiovascular decline due to postprandial hyperglycemia, research suggests.

Poor glycemic control and frequent ER visits are among the signs that a child or adolescent with diabetes may have a depressed mood, according to the results of a study published in the April issue of Pediatrics.

An elevated serum uric acid level increases the likelihood of developing type 2 diabetes in individuals with impaired glucose tolerance at baseline, according to a report in the March issue of Diabetes Care.

Researchers report that treatment with rosiglitazone alone and with atorvastatin improves lipid profiles and reduces levels of certain vascular inflammatory biomarkers in patients with type 2 diabetes.

Use of a blood glucose (BG) monitoring manual improves glycemic control, according to the results of a randomized study.

HDL cholesterol predicts major adverse coronary events independent of other cardiovascular risk factors. A 10mg/dL. decrease in HDL increases risk by 11%, according to a report in the March American Heart Journal.

Something like three out of every five patients with type 2 diabetes show signs of vitamin D deficiency, Italian researchers report.

Glufast, which is close to market is an insulin secretagogue with a rapid onset and short duration of action, lowers post-meal glucose levels by improving the body’s own ability to produce insulin.

After successfully demonstrating that a groundbreaking treatment strategy can reverse type 1 diabetes in animal studies, the FDA has given the go-ahead for researchers from the University of Pittsburgh Medical Center to begin a phase I trial evaluating the treatment in humans.